Dr. Elena Vendrame, MD

Dr. Vendrame practices at Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University.

Dr. Vendrame's NPI, 1598059594, was assigned on June 7, 2011. Dr. Vendrame graduated from University of Padua College of Medicine in 2008. Dr. Vendrame holds California license A129667.

Dr. Vendrame's primary practice is Stanford Hospital at 300 Pasteur Drive, at 300 Pasteur Drive, Stanford, CA 94305 in Santa Clara County. The practice phone is (650) 723-4000.

Dr. Vendrame's primary practice is Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University. The medical group on file is Stanford Health Care. Dmand AI also links Dr. Vendrame to 1 more hospital, named with a free account. Dr. Vendrame's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Vendrame practices, 2 sites in all. Vendor and product names are available with a free account.

Infectious disease is Dr. Vendrame's primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dr. Vendrame is board certified in infectious disease by the American Board of Internal Medicine. Dmand AI has Dr. Vendrame's licenses on file in 2 states: California and Pennsylvania.

Dmand AI lists hiv/aids among the conditions Dr. Vendrame treats.

CMS data shows 52 Medicare services from Dr. Vendrame across 2 procedure codes in 2020, for 14 Medicare patients. Medicare paid $4,207 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 14 Medicare patients who saw Dr. Vendrame in 2024. The largest group is 85 and over, with 0 patients. 75% of them have high cholesterol. Their average risk score is 1.13, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Vendrame's median patient age at 56, with 16% women.

In 2024, Dr. Vendrame wrote 205 Medicare Part D claims for 15 patients. 66% of them were for generic drugs. CMS names the drug for 94 of them, across 6 drugs with 11 or more claims each, at $174,685 in total drug cost. In 2023, CMS named 44 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Vendrame for performance year 2024, reported as part of a group. CMS lists Dr. Vendrame as offering telehealth.

Dmand AI links 27 papers to Dr. Vendrame, published from 2010 to 2025. 2024 was the busiest year, with 4. The most frequent topics are HIV Infections, Killer Cells, Natural and HIV-1. Dr. Vendrame has published most often in Front Immunol. Dr. Vendrame's most frequent co-authors are Catherine Anne Blish, MD, Steven Grant Deeks, MD and Cynthia C. Brinson, MD.

CMS Open Payments shows 1 general payment to Dr. Vendrame from 1 drug or device company in 2024. Food and beverage make up the largest share, 100% of the total. Gilead Sciences, Inc. paid the most, $33.

Dr. Vendrame graduated from University of Padua College of Medicine in 2008.

Dr. Vendrame is in network with 6 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.